Reference number : GC-2017-Q1-00237, amendment number : , agreement type : G, recipient legal name : Simmons, Craig (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Collaborative Health Research Projects, program name french : Projets de recherche concertée sur la santé, program purpose english : Children born with congenital heart diseases, such as tetralogy of Fallot, often have defective_x000D_
heart valves. For example, in tetralogy of Fallot, the pulmonary artery and valve are narrowed._x000D_
Surgeons can enlarge the artery and add a valve leaflet by using a patch made from_x000D_
pericardial tissue from around the heart or a synthetic fabric. While this provides temporary_x000D_
relief to the infant or child, the repair materials cannot grow with the patient and are prone to_x000D_
scarring and calcification, leading to a lifetime of reoperations and clinical interventions for the_x000D_
patient._x000D_
Here, we propose to use principles of heart valve tissue engineering to produce sheets of_x000D_
living valve leaflet tissue that can be used as an alternative repair material. The sheets will be_x000D_
made from stem cells from the infants own umbilical cord grown on a polyurethane mesh,_x000D_
which will eventually dissolve away in the body to harmless byproducts, leaving behind a_x000D_
living valve leaflet produced by the stem cells. To kickstart tissue production, we will first grow_x000D_
the valve tissue in bioreactors that exercise the tissue to improve its strength and flexibility._x000D_
Most engineered valve tissue fails by scarring, so to prevent this, we will inject nanoparticles_x000D_
loaded with an anti-scarring drug into the tissue prior to implantation. We will test this novel_x000D_
replacement tissue in pigs to assess whether the material is durable, does not scar, and_x000D_
remains functional in the body._x000D_
Over the next three years, our interdisciplinary team of material scientists, heart valve_x000D_
experts, and cardiac surgeons will train next-generation engineers, scientists, and surgeons_x000D_
and will collaborate with our partners at SickKids Hospital and Tissue Regeneration_x000D_
Therapuetics to translate this novel concept in congenital heart defect repair towards practice,_x000D_
significant improvement in the current standard of care, and economic impact through_x000D_
commercialization., program purpose french : Children born with congenital heart diseases, such as tetralogy of Fallot, often have defective_x000D_
heart valves. For example, in tetralogy of Fallot, the pulmonary artery and valve are narrowed._x000D_
Surgeons can enlarge the artery and add a valve leaflet by using a patch made from_x000D_
pericardial tissue from around the heart or a synthetic fabric. While this provides temporary_x000D_
relief to the infant or child, the repair materials cannot grow with the patient and are prone to_x000D_
scarring and calcification, leading to a lifetime of reoperations and clinical interventions for the_x000D_
patient._x000D_
Here, we propose to use principles of heart valve tissue engineering to produce sheets of_x000D_
living valve leaflet tissue that can be used as an alternative repair material. The sheets will be_x000D_
made from stem cells from the infants own umbilical cord grown on a polyurethane mesh,_x000D_
which will eventually dissolve away in the body to harmless byproducts, leaving behind a_x000D_
living valve leaflet produced by the stem cells. To kickstart tissue production, we will first grow_x000D_
the valve tissue in bioreactors that exercise the tissue to improve its strength and flexibility._x000D_
Most engineered valve tissue fails by scarring, so to prevent this, we will inject nanoparticles_x000D_
loaded with an anti-scarring drug into the tissue prior to implantation. We will test this novel_x000D_
replacement tissue in pigs to assess whether the material is durable, does not scar, and_x000D_
remains functional in the body._x000D_
Over the next three years, our interdisciplinary team of material scientists, heart valve_x000D_
experts, and cardiac surgeons will train next-generation engineers, scientists, and surgeons_x000D_
and will collaborate with our partners at SickKids Hospital and Tissue Regeneration_x000D_
Therapuetics to translate this novel concept in congenital heart defect repair towards practice,_x000D_
significant improvement in the current standard of care, and economic impact through_x000D_
commercialization., agreement title english : Engineering Pulmonary Valve Tissue for Pediatric Patients with Tetralogy of Fallot, agreement title french : Engineering Pulmonary Valve Tissue for Pediatric Patients with Tetralogy of Fallot, agreement number : CHRPJ, agreement value : 386872.0, agreement start date : 2017-04-25, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2020-2021), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada